Loading…
The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan
Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis....
Saved in:
Published in: | Cancer research (Chicago, Ill.) Ill.), 1997-05, Vol.57 (9), p.1625-1629 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1629 |
container_issue | 9 |
container_start_page | 1625 |
container_title | Cancer research (Chicago, Ill.) |
container_volume | 57 |
creator | SEED, M. P BROWN, J. R FREEMANTLE, C. N PAPWORTH, J. L COLVILLE-NASH, P. R WILLIS, D SOMERVILLE, K. W ASCULAI, S WILLOUGHBY, D. A |
description | Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78971882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78971882</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3</originalsourceid><addsrcrecordid>eNo9kEtLxDAUhYMo4zj6E4Qs1F0lSfNcyuALBtyM65Imt9NIm4xNK8y_t2BxcbgczseBe87QmopSF4pzcY7WhBBdCK7YJbrK-Wu2ghKxQitDS26MXKO0bwGH2IY6jCFFnBrsUpdiwSS2HmJydnAhpt5iDz_QpWMPccQ2-lmHkA4QIYeM6xMe0zE422EfXJcaiNbNxZg9invcnmw3DSnaeI0uGttluFnuBn2-PO-3b8Xu4_V9-7QrWib1WHAJSgqqVE21ZIoZ7axkrGxAe2GEE7rkXjrVGO0tBQ6UNJJ6QZ0mhgCUG_Tw13sc0vcEeaz6kB10nY2QplwpbRTVms3g7QJOdQ--Og6ht8OpWhaa87slt3n-rhlsdCH_Y0xKxjUpfwHhKm-t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78971882</pqid></control><display><type>article</type><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</creator><creatorcontrib>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</creatorcontrib><description>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 9134996</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adenocarcinoma - drug therapy ; Administration, Topical ; Animals ; Antineoplastic agents ; Apoptosis - drug effects ; Biological and medical sciences ; Cell Survival - drug effects ; Chemotherapy ; Colonic Neoplasms - drug therapy ; Cyclooxygenase Inhibitors - administration & dosage ; Diclofenac - administration & dosage ; Hyaluronic Acid - administration & dosage ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mitosis - drug effects ; Neovascularization, Pathologic - prevention & control ; Pharmaceutical Vehicles ; Pharmacology. Drug treatments ; Platelet Endothelial Cell Adhesion Molecule-1 - analysis</subject><ispartof>Cancer research (Chicago, Ill.), 1997-05, Vol.57 (9), p.1625-1629</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2662480$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9134996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SEED, M. P</creatorcontrib><creatorcontrib>BROWN, J. R</creatorcontrib><creatorcontrib>FREEMANTLE, C. N</creatorcontrib><creatorcontrib>PAPWORTH, J. L</creatorcontrib><creatorcontrib>COLVILLE-NASH, P. R</creatorcontrib><creatorcontrib>WILLIS, D</creatorcontrib><creatorcontrib>SOMERVILLE, K. W</creatorcontrib><creatorcontrib>ASCULAI, S</creatorcontrib><creatorcontrib>WILLOUGHBY, D. A</creatorcontrib><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Administration, Topical</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cell Survival - drug effects</subject><subject>Chemotherapy</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>Diclofenac - administration & dosage</subject><subject>Hyaluronic Acid - administration & dosage</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mitosis - drug effects</subject><subject>Neovascularization, Pathologic - prevention & control</subject><subject>Pharmaceutical Vehicles</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Endothelial Cell Adhesion Molecule-1 - analysis</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLxDAUhYMo4zj6E4Qs1F0lSfNcyuALBtyM65Imt9NIm4xNK8y_t2BxcbgczseBe87QmopSF4pzcY7WhBBdCK7YJbrK-Wu2ghKxQitDS26MXKO0bwGH2IY6jCFFnBrsUpdiwSS2HmJydnAhpt5iDz_QpWMPccQ2-lmHkA4QIYeM6xMe0zE422EfXJcaiNbNxZg9invcnmw3DSnaeI0uGttluFnuBn2-PO-3b8Xu4_V9-7QrWib1WHAJSgqqVE21ZIoZ7axkrGxAe2GEE7rkXjrVGO0tBQ6UNJJ6QZ0mhgCUG_Tw13sc0vcEeaz6kB10nY2QplwpbRTVms3g7QJOdQ--Og6ht8OpWhaa87slt3n-rhlsdCH_Y0xKxjUpfwHhKm-t</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>SEED, M. P</creator><creator>BROWN, J. R</creator><creator>FREEMANTLE, C. N</creator><creator>PAPWORTH, J. L</creator><creator>COLVILLE-NASH, P. R</creator><creator>WILLIS, D</creator><creator>SOMERVILLE, K. W</creator><creator>ASCULAI, S</creator><creator>WILLOUGHBY, D. A</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><author>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Administration, Topical</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cell Survival - drug effects</topic><topic>Chemotherapy</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>Diclofenac - administration & dosage</topic><topic>Hyaluronic Acid - administration & dosage</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mitosis - drug effects</topic><topic>Neovascularization, Pathologic - prevention & control</topic><topic>Pharmaceutical Vehicles</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Endothelial Cell Adhesion Molecule-1 - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SEED, M. P</creatorcontrib><creatorcontrib>BROWN, J. R</creatorcontrib><creatorcontrib>FREEMANTLE, C. N</creatorcontrib><creatorcontrib>PAPWORTH, J. L</creatorcontrib><creatorcontrib>COLVILLE-NASH, P. R</creatorcontrib><creatorcontrib>WILLIS, D</creatorcontrib><creatorcontrib>SOMERVILLE, K. W</creatorcontrib><creatorcontrib>ASCULAI, S</creatorcontrib><creatorcontrib>WILLOUGHBY, D. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SEED, M. P</au><au>BROWN, J. R</au><au>FREEMANTLE, C. N</au><au>PAPWORTH, J. L</au><au>COLVILLE-NASH, P. R</au><au>WILLIS, D</au><au>SOMERVILLE, K. W</au><au>ASCULAI, S</au><au>WILLOUGHBY, D. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>57</volume><issue>9</issue><spage>1625</spage><epage>1629</epage><pages>1625-1629</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9134996</pmid><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-5472 |
ispartof | Cancer research (Chicago, Ill.), 1997-05, Vol.57 (9), p.1625-1629 |
issn | 0008-5472 1538-7445 |
language | eng |
recordid | cdi_proquest_miscellaneous_78971882 |
source | EZB-FREE-00999 freely available EZB journals |
subjects | Adenocarcinoma - drug therapy Administration, Topical Animals Antineoplastic agents Apoptosis - drug effects Biological and medical sciences Cell Survival - drug effects Chemotherapy Colonic Neoplasms - drug therapy Cyclooxygenase Inhibitors - administration & dosage Diclofenac - administration & dosage Hyaluronic Acid - administration & dosage Medical sciences Mice Mice, Inbred BALB C Mitosis - drug effects Neovascularization, Pathologic - prevention & control Pharmaceutical Vehicles Pharmacology. Drug treatments Platelet Endothelial Cell Adhesion Molecule-1 - analysis |
title | The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A59%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20inhibition%20of%20colon-26%20adenocarcinoma%20development%20and%20angiogenesis%20by%20topical%20diclofenac%20in%202.5%25%20hyaluronan&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=SEED,%20M.%20P&rft.date=1997-05-01&rft.volume=57&rft.issue=9&rft.spage=1625&rft.epage=1629&rft.pages=1625-1629&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E78971882%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78971882&rft_id=info:pmid/9134996&rfr_iscdi=true |